3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
24
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
2
Recurrence
2
Ovarian Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Lymphatic Abnormalities
2
Lymphangioma, Cystic
2
Lymphangioma
2
Hyperglycemia
2
Hereditary Sensory and Autonomic Neuropathies
2
Vascular Malformations
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Diseases, Vascular
1
Melanoma
1
Hormone Receptor Positive Breast Carcinoma
1
Head and Neck Squamous Cell Cancer
1
Head and Neck Neoplasms
1
HER2-positive Metastatic Breast Cancer
1
Genetic Diseases, Inborn
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Arteriovenous Malformations
1
Advanced HER2+Breast Cancer
1
Advanced Breast Cancer
1
Interventions
pertuzumab
1
Trastuzumab
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced HER2+Breast Cancer
×
Alpelisib
×
1 year
×
Clear all
NCT04208178
2026-04-02
EPIK-B2
Novartis
Phase 3
Active not recruiting
19 enrolled